CJC-1295 exists in two forms in circulation — with and without the drug affinity complex — and they have very different half-lives. Product descriptions frequently do not say which, and the difference is not cosmetic.
19 likes 3mo
Topic summary
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion
This is a generated summary. It shows the 8 most-liked posts from a topic of 54, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
Adding the measurement that post #5 says would settle it.
Ipamorelin selectivity claims originate in preclinical characterisation and are reasonably well supported for what they claim: less effect on cortisol and prolactin than earlier GHRPs. Whether that translates to something clinically meaningful is a different question from whether the selectivity is real.
That holds under the stated conditions and I have stated them.
27 likes 2mo
Post #15 is right about the mechanism and I think understates the practical bit.
Sermorelin and the growth hormone releasing hormone analogues depend on a functioning pituitary response, which is the mechanistic reason they behave differently in different people rather than a dosing problem.
27 likes 2mo
peak_purity, post #1: On the subject in the title: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Working notes rather than a conclusion. Asking about GHRH analogues versus ghrelin mimetics directly, because I have read four threads on it and each answered a slightly different question. The version I want answered is the… Go to post
This follows post #20 rather than contradicting it.
CJC-1295 exists in two forms in circulation — with and without the drug affinity complex — and they have very different half-lives. Product descriptions frequently do not say which, and the difference is not cosmetic.
Written quickly, so the reasoning may be tighter than the wording.
h.brandt, post #4: Answering the question the opening post raises rather than the one it answers. GHRH analogues versus ghrelin mimetics sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly. Go to post
That is a cleaner way of putting what I was circling around.
c.balogun, post #32: This follows post #29 rather than contradicting it. Marking my uncertainty on GHRH analogues versus ghrelin mimetics explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post. Go to post
A methods point on GHRH analogues versus ghrelin mimetics rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference in method.
l.chevalier, post #14: Confirming post #11 from a second method, which matters more than confirming it from a second person. Taking GHRH analogues versus ghrelin mimetics seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences. Go to post
Sermorelin and the growth hormone releasing hormone analogues depend on a functioning pituitary response, which is the mechanistic reason they behave differently in different people rather than a dosing problem.
Read the full topic (54 posts)
This topic was referenced in
- Evidence quality in the secretagogue literature: an honest assessmentCompounds › Secretagogues & GH axis · 2 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Follow-up: Tesamorelin has an approved indication — what that changes about the evidence
Posting this under the heading it deserves: Tesamorelin has an approved indication — what that changes about the evidence Everything below is what sits behind that. What changes if the standard account of…
|
+63 | 68 | 18k | 14mo |
|
Secretagogues and glucose tolerance: the mechanistic concern — what changed since
Secretagogues and glucose tolerance: the mechanistic concern — what changed since Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of…
|
+2 | 6 | 31k | 2mo |
|
About the Secretagogues & GH axis category
Growth-hormone secretagogues and related compounds. Evidence quality here is markedly lower and we say so. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
+6 | 10 | 1.1k | 14mo |
|
What a well-designed human trial of a secretagogue would look like
What a well-designed human trial of a secretagogue would look like I have a specific reason for asking rather than idle curiosity, and the context is below. I was wrong about well-designed human trial in a…
|
2 | 7.2k | 18mo | |
|
Follow-up: Evidence quality in the secretagogue literature: an honest assessment
On the subject in the title: Evidence quality in the secretagogue literature: an honest assessment Working notes rather than a conclusion. A follow-up question about Evidence quality that I did not know to…
|
+20 | 24 | 18k | 4mo |
Related topics — sharing the tags CJC-1295, observational data, ipamorelin
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Follow-up: Tesamorelin has an approved indication — what that changes about the evidence
Posting this under the heading it deserves: Tesamorelin has an approved indication — what that changes about the evidence Everything below is what sits behind that. What changes if the standard account of…
|
+63 | 68 | 18k | 14mo |
|
What would change my mind about repair peptides: a specific answer
What would change my mind about repair peptides: a specific answer — that is the question, and I have not found it answered plainly anywhere I have looked. Documentation question rather than a pharmacological…
|
+26 | 30 | 1.1k | 23h |
|
When a preprint is the best available evidence and we say so — a second dataset
When a preprint is the best available evidence and we say so — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below. A preprint question rather than a…
|
+20 | 24 | 36k | 14mo |
|
Contributing data without breaching anyone's privacy — what changed since
On the subject in the title: Contributing data without breaching anyone's privacy — what changed since Working notes rather than a conclusion. What changes if the standard account of Contributing data without…
|
2 | 58k | 17mo | |
|
Confounding by indication, explained with a concrete example
On the subject in the title: Confounding by indication, explained with a concrete example Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURPASS-2 ( N Engl J Med ,…
|
+21 | 25 | 21k | 11mo |